Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII

Susan Kearney,1,* Leslie J Raffini,2 Tan P Pham,3 Xin Ying Lee,4 Sylvia von Mackensen,5,* Andrea Landorph,6 Hideyuki Takedani,7 Johannes Oldenburg8 1Center for Bleeding and Clotting Disorders, Children’s Hospital Minnesota, Minneapolis, MN, USA; 2Division of Hematology, The Children&r...

Full description

Bibliographic Details
Main Authors:	Kearney S, Raffini LJ, Pham TP, Lee XY, von Mackensen S, Landorph A, Takedani H, Oldenburg J
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-04-01
Series:	Patient Preference and Adherence
Subjects:	Hemophilia A turoctocog alfa pegol Health-Related Quality of Life children adults treatment satisfaction
Online Access:	https://www.dovepress.com/health-related-quality-of-life-and-treatment-satisfaction-of-individua-peer-reviewed-article-PPA

Similar Items

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
by: Napolitano M, et al.
Published: (2021-01-01)

Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy
by: Federica Demma, et al.
Published: (2022-06-01)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
by: Steven R. Lentz, et al.
Published: (2022-02-01)

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
by: Eichler H, et al.
Published: (2023-11-01)

Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
by: Ilaria Nichele, et al.
Published: (2024-04-01)

Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
by: Benson G, et al.
Published: (2021-01-01)

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
by: Wu R, et al.
Published: (2020-06-01)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
by: Masahiro Takeyama, et al.
Published: (2020-10-01)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
by: Ezio Zanon
Published: (2023-08-01)

Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis
by: Chonlatis Srichumpuang, et al.
Published: (2024-03-01)

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety
by: Reinhard Stidl, et al.
Published: (2018-07-01)

Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States
by: Wu Y, et al.
Published: (2022-09-01)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
by: Anthony K. Chan, et al.
Published: (2020-10-01)

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
by: Davide Matino, et al.
Published: (2022-03-01)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
by: Vashi P, et al.
Published: (2021-11-01)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
by: Takedani H, et al.
Published: (2015-03-01)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
by: Kenet G, et al.
Published: (2023-06-01)

Treatment With Efmoroctocog Alfa (Elocta®) in Hemophilia: A Case Series
by: Ezio Zanon, et al.
Published: (2020-10-01)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
by: Klamroth R, et al.
Published: (2021-11-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
by: Maria Majdan, et al.
Published: (2014-07-01)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
by: Johnny Mahlangu, et al.
Published: (2021-08-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva, et al.
Published: (2015-10-01)

Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa
by: Matteo Nicola Dario Di Minno, et al.
Published: (2020-04-01)

Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
by: I.L. Khalif, et al.
Published: (2018-04-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
by: I L Khalif, et al.
Published: (2018-04-01)

Certolizumab pegol in the treatment of spondyloarthritis
by: Mariusz Korkosz
Published: (2014-09-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
by: Mehmet Baysal, et al.
Published: (2018-09-01)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
by: A. Spadaro, et al.
Published: (2013-07-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
by: P. I. Novikov, et al.
Published: (2018-07-01)

Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis
by: Francesco Carubbi, et al.
Published: (2020-10-01)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
by: Mariasanta Napolitano, et al.
Published: (2019-11-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
by: Piotr Wiland, et al.
Published: (2011-08-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
by: Emna Hannech, et al.
Published: (2021-06-01)

Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study
by: Giannis Chatzimichail, et al.
Published: (2022-04-01)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
by: Hassan Abolghasemi, MD, et al.
Published: (2018-06-01)

Strategies to encourage physical activity in patients with hemophilia to improve quality of life
by: Goto M, et al.
Published: (2016-05-01)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
by: Daniel P. Hart
Published: (2020-07-01)

Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris
by: Keiko Yamaguchi, et al.
Published: (2018-12-01)

Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol
by: Walter P. Maksymowych, et al.
Published: (2021-10-01)